Cargando…
The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332535/ https://www.ncbi.nlm.nih.gov/pubmed/32620125 http://dx.doi.org/10.1186/s12967-020-02423-8 |
_version_ | 1783553546206052352 |
---|---|
author | Wang, Fang Qu, Mengyuan Zhou, Xuan Zhao, Kai Lai, Changxiang Tang, Qiyuan Xian, Wenjie Chen, Ruikun Li, Xuan Li, Zhiyu He, Qing Liu, Lei |
author_facet | Wang, Fang Qu, Mengyuan Zhou, Xuan Zhao, Kai Lai, Changxiang Tang, Qiyuan Xian, Wenjie Chen, Ruikun Li, Xuan Li, Zhiyu He, Qing Liu, Lei |
author_sort | Wang, Fang |
collection | PubMed |
description | BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People’s Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression. RESULTS: Of all the 333 patients, 70 (21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253 (76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80 [1.72, 8.52]), males (2.21 [1.20, 4.07]), with comorbidities (1.78 [1.13, 2.81]) certain exposure history (0.38 [0.20, 0.71]), abnormal radiology manifestations (3.56 [1.13, 11.40]), low level of T lymphocytes (0.99 [0.997, 0.999]), high level of NLR (0.99 [0.97, 1.01]), IL-6 (1.05 [1.03, 1.07]) and CRP (1.67 [1.12, 2.47]) were the risk factors of disease progression by logistic regression. CONCLUSIONS: The potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage. |
format | Online Article Text |
id | pubmed-7332535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73325352020-07-06 The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China Wang, Fang Qu, Mengyuan Zhou, Xuan Zhao, Kai Lai, Changxiang Tang, Qiyuan Xian, Wenjie Chen, Ruikun Li, Xuan Li, Zhiyu He, Qing Liu, Lei J Transl Med Research BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People’s Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression. RESULTS: Of all the 333 patients, 70 (21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253 (76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80 [1.72, 8.52]), males (2.21 [1.20, 4.07]), with comorbidities (1.78 [1.13, 2.81]) certain exposure history (0.38 [0.20, 0.71]), abnormal radiology manifestations (3.56 [1.13, 11.40]), low level of T lymphocytes (0.99 [0.997, 0.999]), high level of NLR (0.99 [0.97, 1.01]), IL-6 (1.05 [1.03, 1.07]) and CRP (1.67 [1.12, 2.47]) were the risk factors of disease progression by logistic regression. CONCLUSIONS: The potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage. BioMed Central 2020-07-03 /pmc/articles/PMC7332535/ /pubmed/32620125 http://dx.doi.org/10.1186/s12967-020-02423-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wang, Fang Qu, Mengyuan Zhou, Xuan Zhao, Kai Lai, Changxiang Tang, Qiyuan Xian, Wenjie Chen, Ruikun Li, Xuan Li, Zhiyu He, Qing Liu, Lei The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
title | The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
title_full | The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
title_fullStr | The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
title_full_unstemmed | The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
title_short | The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
title_sort | timeline and risk factors of clinical progression of covid-19 in shenzhen, china |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332535/ https://www.ncbi.nlm.nih.gov/pubmed/32620125 http://dx.doi.org/10.1186/s12967-020-02423-8 |
work_keys_str_mv | AT wangfang thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT qumengyuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT zhouxuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT zhaokai thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT laichangxiang thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT tangqiyuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT xianwenjie thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT chenruikun thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT lixuan thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT lizhiyu thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT heqing thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT liulei thetimelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT wangfang timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT qumengyuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT zhouxuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT zhaokai timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT laichangxiang timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT tangqiyuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT xianwenjie timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT chenruikun timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT lixuan timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT lizhiyu timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT heqing timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina AT liulei timelineandriskfactorsofclinicalprogressionofcovid19inshenzhenchina |